I will try and keep this succinct.
1. Bells handled the recent CR and underwrote it. They have a lot shortfall shares they are looking to sell. They want to cash at profit to move onto the next play, reduce opportunity cost of capital. A tool in the brokers arsenal is the research report to be able to do this. Make liquidity, generate hype and set a big price target.
2. Wilsons issuing a research report and buying is a good sign. It also explains their conviction buying, they have the support of their clients. They don't have a heap of shortfall shares to sell off. They see value in buying purely from the FA of the company. They may have had a few clients who got their fill in the CR but them buying above 16c is a positive to me.
I have only showed one month of data. I only care about trading short tem price moves and the broker data does add some colour to the chart. I like the chart and I'll trade it.
- Forums
- ASX - By Stock
- OSL
- Ann: OncoSil receives Swiss regulatory approval
OSL
oncosil medical ltd
Add to My Watchlist
15.7%
!
$1.18

Ann: OncoSil receives Swiss regulatory approval, page-58
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.18 |
Change
0.160(15.7%) |
Mkt cap ! $16.78M |
Open | High | Low | Value | Volume |
$1.05 | $1.18 | $1.03 | $42.42K | 39.29K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 325 | $1.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.16 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 325 | 1.130 |
1 | 14466 | 1.125 |
1 | 5000 | 1.120 |
1 | 7500 | 1.080 |
1 | 15000 | 1.050 |
Price($) | Vol. | No. |
---|---|---|
1.160 | 2000 | 1 |
1.170 | 2775 | 1 |
1.180 | 272 | 1 |
1.195 | 830 | 1 |
1.200 | 65603 | 3 |
Last trade - 13.33pm 26/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online